Prolonged higher dose methylprednisolone <italic>versus</italic> conventional dexamethasone in COVID-19 pneumonia: a randomised controlled trial (MEDEAS)

Prolonged higher dose methylprednisolone versus conventional dexamethasone in COVID-19 pneumonia: a randomised controlled trial (MEDEAS)

Francesco Salton, Paola Confalonieri, Stefano Centanni, Michele Mondoni, Nicola Petrosillo, Paolo Bonfanti, Giuseppe Lapadula, Donato Lacedonia, Antonio Voza, Nicoletta Carpenè, Marcella Montico, Nicolò Reccardini, Gianfranco Umberto Meduri, Barbara Ruaro, Marco Confalonieri

Source: Eur Respir J, 61 (4) 2201514; 10.1183/13993003.01514-2022

Journal Issue: April

Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Francesco Salton, Paola Confalonieri, Stefano Centanni, Michele Mondoni, Nicola Petrosillo, Paolo Bonfanti, Giuseppe Lapadula, Donato Lacedonia, Antonio Voza, Nicoletta Carpenè, Marcella Montico, Nicolò Reccardini, Gianfranco Umberto Meduri, Barbara Ruaro, Marco Confalonieri. Prolonged higher dose methylprednisolone versus conventional dexamethasone in COVID-19 pneumonia: a randomised controlled trial (MEDEAS). Eur Respir J, 61 (4) 2201514; 10.1183/13993003.01514-2022

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.